Literature DB >> 2676012

Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells.

M P Everson1, C B Brown, M B Lilly.   

Abstract

Previous studies suggest that malignant cells from some patients with myeloid leukemias produce colony-stimulating factors (CSFs) that can function as autocrine growth factors in vitro. We have examined the roles of interleukin-6 (IL-6) and granulocyte-macrophage CSF (GM-CSF) in the proliferation of myeloid leukemia cells. IL-6 activity was assessed in conditioned medium (CM) from myeloid leukemia cell cultures or cell lysates using IL-6-dependent KD83 and 7TD1 murine cell lines. Media conditioned by cells from patients with chronic myelomonocytic leukemia (CMMoL), but not by normal monocytes, chronic myelogenous leukemia (CML), or acute myelogenous leukemia (AML) cells, contained substantial levels (50 to 1,000 U/10(6) cells) of IL-6. The IL-6 content of CM correlated directly with donor peripheral blood WBC count. CM from two of five CMMoL samples also contained greater than 350 pg/mL GM-CSF. Moreover, CMMoL cells spontaneously formed colonies in semisolid medium. CMMoL colony formation could be partially inhibited by antibodies to IL-6 or GM-CSF, whereas combination of these antibodies gave additive, and nearly complete (greater than 93%), inhibition of spontaneous colony formation. Cell lysates from uncultured CMMoL cells from one patient contained abundant GM-CSF protein but no detectable IL-6. These data suggest that IL-6 and GM-CSF act in vitro as autocrine growth factors for CMMoL cells, and that CMMoL cells in vivo may represent a GM-CSF-dependent autocrine growth system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2676012

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Translational hematology.

Authors:  Klaus Geissler
Journal:  Wien Med Wochenschr       Date:  2014-09-10

2.  Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells.

Authors:  K Akashi; T Shibuya; M Harada; Y Takamatsu; N Uike; T Eto; Y Niho
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 3.  Interleukin-6 in clinical medicine.

Authors:  J Bauer; F Herrmann
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

Review 4.  Therapy for Chronic Myelomonocytic Leukemia in a New Era.

Authors:  Tamara K Moyo; Michael R Savona
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

5.  Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells.

Authors:  K Geissler; L Ohler; M Födinger; I Virgolini; M Leimer; E Kabrna; M Kollars; S Skoupy; B Bohle; M Rogy; K Lechner
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

6.  Characteristics of granulocyte-macrophage colony formation in chronic myelomonocytic leukemia: a comparative study with other myelodysplastic and myeloproliferative disorders.

Authors:  A Yuo; K Miyazono; A Urabe; F Takaku
Journal:  Jpn J Cancer Res       Date:  1990-08

7.  Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.

Authors:  Klaus Geissler; Eva Jäger; Agnes Barna; Michael Gurbisz; Temeida Graf; Elmir Graf; Thomas Nösslinger; Michael Pfeilstöcker; Sigrid Machherndl-Spandl; Reinhard Stauder; Armin Zebisch; Heinz Sill; Leopold Öhler; Rajko Kusec; Gregor Hörmann; Peter Valent
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.